AG真人官方

Morgan Stanley Finance LLC (Series A Global Medium-Term Notes) 鈥� Preliminary Pricing Supplement No. 9,133 announces the launch of Callable Jump Notes due Aug-1-2030 that are fully and unconditionally guaranteed by Morgan Stanley. The $1,000-denominated securities are linked to the S&P 500 Futures Excess Return Index (SPXFP) and are designed to return principal at a minimum, while offering either (i) a stepped, call-triggered redemption schedule beginning Jul-31-2026, or (ii) 120% participation in index appreciation at maturity if the notes are not called and the final index level exceeds the initial level.

Key structural terms

• Issue price: $1,000; estimated value on pricing date: 鈮�$933.20 (down ~6.7% from issue price due to fees and internal funding rate).
• Strike & pricing date: Jul-28-2025; maturity: Aug-1-2030 (鈮�5-year term after first call eligibility).
• Call feature: MS may redeem in whole (not in part) on any of 48 predefined quarterly dates if a risk-neutral valuation model deems redemption economically rational. Minimum call price rises 鈮�$10 every date, equating to an annualized return of 鈮�12% on the first call and 鈮�11% over the life of the schedule.
• Payment at maturity (if not called): 鈥� If Final > Initial, investor receives principal + 120% 脳 index gain. 鈥� If Final 鈮� Initial, investor receives principal only. No downside exposure below principal.
• No periodic coupons; principal protection only at maturity; senior unsecured obligations of MSFL, guaranteed by Morgan Stanley.
• Not listed on any exchange; MS & Co. may make markets but is not obligated to do so; expected limited secondary liquidity.

Risk highlights

• Credit risk: repayment dependent on Morgan Stanley; notes are unsecured.
• Call/early-redemption risk: issuer has unilateral right to redeem when it is most advantageous to Morgan Stanley, capping upside; investors bear reinvestment risk.
• Value erosion: Estimated value < issue price due to distribution, structuring and hedging costs plus an internal funding rate below MS secondary spreads.
• Zero coupon & inflation risk: no interim interest; if index does not appreciate investors earn 0% before inflation.
• Taxation: expected treatment as Contingent Payment Debt Instrument (CPDI); holders must accrue phantom income annually.
• Liquidity risk: no listing; secondary market prices likely below par and below estimated value; bid/offer spread applies.

The offering caters to investors seeking principal protection with potential equity upside, who are willing to accept issuer credit exposure, call risk and a negative issue-to-value differential in exchange for 鈮�12% potential annualized call premiums or 120% equity participation at maturity.

Bank of Nova Scotia (BNS) is marketing Autocallable Leveraged Index Return Notes庐 (LIRNs) linked to the Nasdaq-100 Index庐 with a scheduled maturity in July 2028. The $10 face-value notes feature a single observation date about one year after pricing. If on that date the Index closes at or above its starting level, the notes are automatically called for $11.00 per unit, delivering a 10% absolute return and terminating the investment early.

If not called, holders participate in Index appreciation at a leverage factor to be fixed between 140%-160%. For example, at the indicative midpoint of 150%, a 20% Index rise would generate a 30% note return. There is no upside cap other than the leverage multiple. However, principal is fully at risk: if the Ending Value falls below the Starting Value, investors are exposed to a 1-for-1 loss of principal, down to zero, because the threshold is set at 100% of the Starting Value.

All payments rely on the senior unsecured credit of BNS. The initial estimated value is projected between $9.26 and $9.56, below the $10 public offer price, reflecting a $0.20 underwriting discount and a $0.05 hedging-related charge. Minimum purchase is 100 units, and investors buying 鈮�300,000 units in household accounts receive a $0.05 price concession. The notes will not be listed, and BofA Securities (calculation agent) is under no obligation to provide secondary liquidity.

Key terms:

• Principal Amount: $10 per unit
• Term: ~3 years if not called
• Call Level: 100% of Starting Value (Observation Date ~July 2026)
• Call Amount: $11.00 (includes $1.00 premium, 10%)
• Participation Rate: 140%-160% (set on pricing date)
• Threshold & Downside: 100% 鈥� full downside exposure
• Issuer Credit: senior unsecured claim on BNS; not FDIC/CDIC insured
• Secondary Market: none expected; any repurchases at issuer/agent discretion

Risk highlights detailed in the term sheet include potential loss of entire principal, valuation below issue price due to internal funding rate, limited liquidity, tax uncertainties under U.S. and Canadian law, and conflicts of interest as BofA Securities acts as calculation agent and hedging counterparty.

The product suits investors who are moderately bullish on the Nasdaq-100 over the next 12 months, can tolerate full downside risk, and do not require interim income or liquidity. It is not appropriate for capital-preservation objectives.

Everi Holdings Inc. (EVRI) has filed Form 25 with the U.S. Securities and Exchange Commission, notifying the SEC and investors that its common stock is being removed from listing and registration on the New York Stock Exchange (NYSE) pursuant to Section 12(b) of the Securities Exchange Act of 1934.

The filing, signed on 1 July 2025 by NYSE representative Tyler Mastronardi, certifies that the Exchange has satisfied all applicable rules under 17 CFR 240.12d2-2(b) for striking the security from listing. No financial statements, earnings data, or explanatory detail regarding the cause of delisting are provided in the document.

• Issuer: Everi Holdings Inc., 7250 S. Tenaya Way, Suite 100, Las Vegas, NV 89113; Tel: (702) 855-3006
• Security affected: Common Stock
• Exchange: New York Stock Exchange LLC
• Action: Removal from listing and/or registration under Rule 12d2-2

The notice indicates either the NYSE or the company (or both) initiated the delisting process in accordance with Exchange and SEC rules, but the form does not specify the underlying reason, effective date, or post-delisting trading venue.

Greif, Inc. (NYSE: GEF) has entered into a definitive agreement to divest its entire containerboard business鈥攈eld through Greif Containerboard Solutions, LLC (GCS) and Box-Board Holding Corporation (BBH)鈥攖o Packaging Corporation of America (PCA) for $1.8 billion in cash, subject to customary adjustments. The transaction was executed on June 30, 2025 and disclosed via Form 8-K on July 1, 2025.

Under the Purchase and Sale Agreement, Greif Packaging LLC (the 鈥淪eller鈥�) will first contribute all containerboard assets鈥攎ills, sheet feeder facilities, equipment and related items鈥攖o GCS. PCA will then acquire 100 % of the Seller鈥檚 equity interests in both GCS and BBH. Closing is conditioned on standard requirements, most notably the expiration or early termination of the Hart-Scott-Rodino (HSR) antitrust waiting period.

Outside Date & Termination: Either party may terminate if closing has not occurred by June 30, 2026, with up to two 90-day extensions available (one mutual, one at Greif鈥檚 option). Additional termination rights exist for mutual consent, non-appealable governmental prohibition, or uncured breaches of representations, warranties or covenants by either party.

The filing cautions investors not to rely solely on the representations and warranties within the agreement for factual determinations, noting that conditions may change over time. A related press release dated July 1, 2025 (Exhibit 99.1) announces the divestiture, and the full Agreement is furnished as Exhibit 10.1.

Strategic Implications: If completed, the sale will bring a substantial influx of cash and marks Greif鈥檚 exit from the containerboard segment, potentially reshaping its product portfolio toward remaining industrial packaging operations. However, completion risk remains until all regulatory and contractual conditions are met.

Greif, Inc. (NYSE: GEF) has entered into a definitive agreement to divest its entire containerboard business鈥攈eld through Greif Containerboard Solutions, LLC (GCS) and Box-Board Holding Corporation (BBH)鈥攖o Packaging Corporation of America (PCA) for $1.8 billion in cash, subject to customary adjustments. The transaction was executed on June 30, 2025 and disclosed via Form 8-K on July 1, 2025.

Under the Purchase and Sale Agreement, Greif Packaging LLC (the 鈥淪eller鈥�) will first contribute all containerboard assets鈥攎ills, sheet feeder facilities, equipment and related items鈥攖o GCS. PCA will then acquire 100 % of the Seller鈥檚 equity interests in both GCS and BBH. Closing is conditioned on standard requirements, most notably the expiration or early termination of the Hart-Scott-Rodino (HSR) antitrust waiting period.

Outside Date & Termination: Either party may terminate if closing has not occurred by June 30, 2026, with up to two 90-day extensions available (one mutual, one at Greif鈥檚 option). Additional termination rights exist for mutual consent, non-appealable governmental prohibition, or uncured breaches of representations, warranties or covenants by either party.

The filing cautions investors not to rely solely on the representations and warranties within the agreement for factual determinations, noting that conditions may change over time. A related press release dated July 1, 2025 (Exhibit 99.1) announces the divestiture, and the full Agreement is furnished as Exhibit 10.1.

Strategic Implications: If completed, the sale will bring a substantial influx of cash and marks Greif鈥檚 exit from the containerboard segment, potentially reshaping its product portfolio toward remaining industrial packaging operations. However, completion risk remains until all regulatory and contractual conditions are met.

Inozyme Pharma, Inc. (NASDAQ: INZY) filed Post-Effective Amendment No. 1 to deregister securities remaining under two previously effective shelf Registration Statements on Form S-3 (Nos. 333-258702 and 333-275364). The shelves collectively covered up to $500 million of common stock, preferred stock, debt, depositary shares, subscription rights, warrants and units. As of July 1, 2025, none of the registered securities remain available for sale.

The amendment follows the consummation of Inozyme鈥檚 merger with BioMarin Pharmaceutical Inc. Under the Agreement and Plan of Merger dated May 16, 2025, Incline Merger Sub, Inc. merged with and into Inozyme, making Inozyme a wholly-owned subsidiary of BioMarin as of July 1, 2025. Consequently, all outstanding offerings under the shelves were terminated and the company is removing any unsold securities from registration pursuant to its undertaking under Rule 415.

This filing is largely administrative, signaling the formal close-out of Inozyme鈥檚 capital-raising capability as a standalone public entity and completing one of the final SEC steps associated with the transaction.

Inozyme Pharma, Inc. (INZY) filed Post-Effective Amendment No. 1 to its two shelf registration statements (Nos. 333-258702 and 333-275364) to deregister all remaining unsold securities, which had allowed for the issuance of up to $500 million of common stock, preferred stock, debt securities and related instruments. The amendment follows the closing of the previously announced merger completed on July 1, 2025, in which Incline Merger Sub, Inc., a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., merged with and into Inozyme, leaving Inozyme as a wholly-owned subsidiary of BioMarin. Because the merger terminates any independent public offering activity, the company is withdrawing the shelves and terminating their effectiveness.

On July 1, 2025, Director Richard J. Salute filed a Form 4 reporting that on June 30, 2025 he received 2,283 restricted shares of NewtekOne, Inc. (NEWT) common stock under the shareholder-approved 2023 Stock Incentive Plan. The award is coded 鈥淎鈥� (grant) at an indicated price of $10.95 per share and will vest 100 % after 12 months. Any dividends declared during the restricted period will be paid in additional common shares that follow the same vesting schedule. After this grant, Salute鈥檚 direct beneficial ownership increases to 41,505 shares. No derivative securities or open-market transactions were disclosed, and the filing was submitted solely by the reporting person.

In Amendment No. 3 to its Schedule 14D-9, Inozyme Pharma, Inc. (INZY) discloses that BioMarin Pharmaceutical Inc., through its subsidiary Incline Merger Sub, has successfully completed its all-cash tender offer at $4.00 per share for all outstanding INZY common stock.

The offer expired one minute after 11:59 p.m. ET on June 30, 2025, with 45,455,118 shares鈥攁辫辫谤辞虫颈尘补迟别濒测 69.8 % of outstanding shares鈥攙alidly tendered and not withdrawn, thereby meeting the minimum condition. On July 1, 2025, the purchaser accepted and will promptly pay for all validly tendered shares.

Immediately after acceptance, the parties effected a Section 251(h) DGCL merger without a separate shareholder vote. Inozyme survived the merger and became a wholly owned subsidiary of BioMarin. Each remaining share (other than excluded or appraisal-eligible shares) was automatically converted into the right to receive the same $4.00 cash consideration, net of any required withholding taxes.

Following closing, INZY shares ceased trading on the Nasdaq Global Select Market and will be delisted. BioMarin intends to terminate the registration of Inozyme鈥檚 securities and suspend INZY鈥檚 periodic reporting obligations under the Exchange Act as soon as practicable.